Skip to content
Menu

RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $77

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and raises the price target from $75 to $77.

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and raises the price target from $75 to $77.

Read at benzinga.com